Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1985 1
1989 3
1992 1
1993 1
1994 1
1995 1
1996 1
1997 1
1999 2
2000 1
2004 1
2006 1
2008 2
2009 2
2010 6
2011 5
2012 2
2013 1
2014 4
2015 2
2016 1
2017 1
2018 1
2019 4
2020 5
2021 5
2022 1
2023 2
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, Xu B, Wardley A, Kaen D, Andrade L, Semiglazov V, Reinisch M, Patel S, Patre M, Morales L, Patel SL, Kaul M, Barata T, O'Shaughnessy J; IMpassion131 investigators. Miles D, et al. Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1. Ann Oncol. 2021. PMID: 34219000 Free article. Clinical Trial.
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Balmaña J, Fasching PA, Couch FJ, Delaloge S, Labidi-Galy I, O'Shaughnessy J, Park YH, Eisen AF, You B, Bourgeois H, Gonçalves A, Kemp Z, Swampillai A, Jankowski T, Sohn JH, Poddubskaya E, Mukhametshina G, Aksoy S, Timcheva CV, Park-Simon TW, Antón-Torres A, John E, Baria K, Gibson I, Gelmon KA; LUCY investigators. Balmaña J, et al. Breast Cancer Res Treat. 2024 Apr;204(2):237-248. doi: 10.1007/s10549-023-07165-x. Epub 2023 Dec 19. Breast Cancer Res Treat. 2024. PMID: 38112922 Free PMC article. Clinical Trial.
Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity.
Frassoldati A, Biganzoli L, Bordonaro R, Cinieri S, Conte P, Laurentis M, Mastro LD, Gori S, Lauria R, Marchetti P, Michelotti A, Montemurro F, Naso G, Pronzato P, Puglisi F, Tondini CA. Frassoldati A, et al. Among authors: naso g. Future Oncol. 2020 Feb;16(5):129-145. doi: 10.2217/fon-2018-0942. Epub 2019 Dec 18. Future Oncol. 2020. PMID: 31849236 Review.
ABE8e adenine base editor precisely and efficiently corrects a recurrent COL7A1 nonsense mutation.
Sheriff A, Guri I, Zebrowska P, Llopis-Hernandez V, Brooks IR, Tekkela S, Subramaniam K, Gebrezgabher R, Naso G, Petrova A, Balon K, Onoufriadis A, Kujawa D, Kotulska M, Newby G, Łaczmański Ł, Liu DR, McGrath JA, Jacków J. Sheriff A, et al. Among authors: naso g. Sci Rep. 2022 Nov 16;12(1):19643. doi: 10.1038/s41598-022-24184-8. Sci Rep. 2022. PMID: 36385635 Free PMC article.
Pancreatic cancer: from molecular signature to target therapy.
Longo R, Cacciamani F, Naso G, Gasparini G. Longo R, et al. Among authors: naso g. Crit Rev Oncol Hematol. 2008 Dec;68(3):197-211. doi: 10.1016/j.critrevonc.2008.03.003. Epub 2008 Apr 23. Crit Rev Oncol Hematol. 2008. PMID: 18436450 Review.
Overcoming endocrine resistance in breast cancer.
Madaio RA, Spalletta G, Cravello L, Ceci M, Repetto L, Naso G. Madaio RA, et al. Among authors: naso g. Curr Cancer Drug Targets. 2010 Aug;10(5):519-28. doi: 10.2174/156800910791517226. Curr Cancer Drug Targets. 2010. PMID: 20384578 Review.
56 results